Third-party inspections
This article was originally published in The Gray Sheet
Executive Summary
Sen. Edward Kennedy (D-Mass.) will monitor the progress of the U.S./EU mutual recognition agreement (MRA) program before committing to any proposal authorizing third-party inspections of medical device manufacturers, HELP Committee staff suggests. Third-party inspection and review provisions within the Greenwood/Eshoo device reform measure (HR 3580) were chief obstacles to device user fee passage as part of the PDUFA reauthorization package currently awaiting the President's signature (1"The Gray Sheet" May 27, 2002, p. 3). Although industry proponents, including AdvaMed, still hope to fasten user fees to Greenwood/Eshoo, HELP staffers indicate Kennedy remains opposed to third-party reforms without evidence of their benefit. Among issues to be resolved are whether third-party inspections can be conducted while avoiding conflicts of interest. The General Accounting Office has indicated that data are insufficient for analysis of third-party and reuse issues requested by Kennedy earlier this year...
You may also be interested in...
Kennedy To Industry: User Fees Still In Play If Third Party Sits This One Out
Industry supporters of medical device user fees are assuming a formidable challenge by linking the legislative proposal with the "Medical Device Amendments of 2001" (HR 3580), introduced by Reps. Jim Greenwood (R-Penn.) and Anna Eshoo (D-Calif.)
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.